Congenital Parvovirus B19 Infection

Summary

Congenital parvovirus B19 infection is caused by a single-stranded DNA virus that infects maternal erythroid progenitor cells and can cross the placenta, leading to fetal anemia, hydrops fetalis, miscarriage, or stillbirth, most commonly in the first and second trimesters. Maternal infection is often mild or asymptomatic, while fetal infection is monitored through PCR testing, serial ultrasounds, and Doppler studies. Management includes supportive care for the mother and intrauterine transfusions for severely affected fetuses, with prevention focused on hand hygiene and minimizing exposure in high-risk settings.

Epidemiology

Parvovirus B19 infection affects approximately 5% of pregnant women annually in the United States, with higher prevalence among daycare workers and elementary school teachers. Vertical transmission occurs in up to one-third of maternal infections, and spontaneous miscarriage or intrauterine death occurs in roughly 9% of affected pregnancies. Most intrauterine infections, however, do not result in congenital malformations.

Pathogen and Mechanism

Parvovirus B19 is a single-stranded DNA virus that primarily infects erythroid progenitor cells in the bone marrow and endothelial cells via the P antigen. Viral replication causes cell destruction, leading to fetal hydrops and severe anemia in neonates, or pure red blood cell aplasia in adults.

Transmission

• Maternal: Mainly via respiratory droplets; rare hematogenous transmission.

• Fetal: Transplacental from an infected mother.

Clinical Features

Maternal

• Often asymptomatic or mild self-limiting illness.

• Symmetrical arthralgia (proximal interphalangeal joints, knees).

• Low-grade fever, malaise, headache, or upper respiratory symptoms.

Pediatric/Childhood Presentation

• Erythema infectiosum (“slapped cheek syndrome”)

• Mild fever, malaise, and upper respiratory symptoms

Fetal

• Severe anemia

• Hydrops fetalis

• Miscarriage or stillbirth (approx. 10%, highest risk in the first and second trimesters)

Diagnosis

Maternal

• Serology: Parvovirus B19-specific IgM and IgG antibodies
  
  

Fetal

• PCR for parvovirus B19 DNA (amniotic fluid or fetal blood)

• Serial ultrasound and Doppler studies of fetal vessels (every 1–2 weeks)

• Fetal hemoglobin assessment via umbilical vein sampling if Doppler suggests anemia

Management

Maternal

• Infection is self-limiting; symptomatic treatment with antipyretics or analgesics is sufficient

• Referral to a fetal medicine specialist for confirmed infection

Fetal

• Serial ultrasound and Doppler monitoring beginning 4 weeks post-infection or at 16 weeks, repeated every 1–2 weeks until 30 weeks gestation

• Intrauterine fetal blood transfusion for severe anemia

• Additional platelet transfusion if thrombocytopenia is present

Prevention

• Frequent hand hygiene

• Avoiding exposure to high-risk environments (schools, pediatric clinics) for pregnant women at risk of TORCH infections